BYD to use Baidu Apollo’s autonomous driving technology in its EVs as it raises its game against Tesla, domestic rivals Artificial intelligence giant Baidu will supply its Apollo Navigation Pilot smart driving services and products, according to two sources It marks an important step for Beijing-based Baidu as it strives to commercialise its Apollo self-driving technologies after nearly five year of development Post BYD, established in 1995 as a battery manufacturer, has evolved into the mainland’s largest new-energy vehicle maker. Photo: SOPA Images/LightRocket via Getty Images
BYD Partners with Nuro to Manufacture All-Electric Autonomous Delivery Vehicle LOS ANGELES, CALIF.– (1/13/2022) — BYD Co., Ltd. announced its partnership with leading autonomous vehicle company Nuro to begin producing the company’s third-generation electric autonomous delivery vehicle. The partnership is expected to scale Nuro’s more affordable, eco-friendly, and convenient services to millions of people across the country. Nuro’s third-generation electric autonomous delivery vehicle nicknamed Stoney “BYD will leverage the manufacturing capacity of our Lancaster, California plant by finishing assembly of globally sourced hardware components to support Nuro and bring more jobs to the community,” said Stella Li, Executive Vice President of BYD Co. Ltd. and President of BYD North America, “Together we will build this autonomous delivery vehicle, with the mutual goal of creating a safer environment on streets across the United States.” Today’s announcement follows Nuro’s $600 million Series D funding round which closed in Q4 2021 and was led by Tiger Global Management with participation from other investors.
XAIR (XAIR) 6.99+0.35(+5.27%)<------------- Up Friday? At close: April 22 04:00PM EDT 7.20+0.21(+3.00%)<------- Pre-Market:09:27AM EDT
E.F Hutton is back from dead Splash Beverage initiated with a Buy at EF Hutton 08:46 SBEV EF Hutton analyst Ben Piggott initiated coverage of Splash Beverage with a Buy rating and $5 price target. He believes that Splash's emerging portfolio of brands and executives' industry experience can lead to sustained "hyper-growth" through at least 2023, Piggott tells investors. He likes management's plan to use Splash as a vehicle to acquire other up-and-coming beverage brands, the analyst added. SBEV-$2.45
Beyond Air presents safety, efficacy data from LungFit PRO study 07:54 XAIR Beyond Air announced positive safety and efficacy data from the LungFit PRO pilot study of high-concentration inhaled NO in Community-Acquired Viral Pneumonia, CAVP, including COVID-19. The multi-center, open-label, randomized clinical trial in Israel enrolled a total of 40 subjects hospitalized for CAVP, who were randomized in a 1:1 ratio to receive inhalations of 150 ppm NO given intermittently for 40 minutes four times per day for up to seven days in addition to standard supportive treatment or standard supportive treatment alone. Enrolled patients were followed for a 180-day period. The study endpoints include safety, time on oxygen supplementation and hospital length of stay, among others. The data show that inhaled NO treatment in patients with COVID-19 and other CAVP was well tolerated overall, and safe, with improved efficacy parameters as compared to SST. Safety data from the study show that inhaled NO treatment was well tolerated overall with no treatment related adverse events as assessed by the investigators. There were two SAEs reported in the group receiving inhaled NO along with SST, which were determined to be related to underlying conditions and unrelated to study drug/device. "These data from the pilot study of LungFit Pro in CAVP patients show consistency of improvement demonstrated across important disease related assessments. We believe these results show that high concentration inhaled NO could be an effective treatment for patients hospitalized with COVID-19," said Steve Lisi, Chairman and Chief Executive Officer of Beyond Air. "The data presented today at ECCMID further expand upon our growing portfolio of clinical data showing high concentration NO as a potentially safe and effective treatment for various upper and lower respiratory infections. These extensive data have proven inhaled NO has antimicrobial, anti-inflammatory and vasodilator properties."
SIMO IS AN OLD FRIEND OF OURS=== I STILL OWN.... FROM TWO THREADS AGO..... Beyond the ongoing TWTR soap opera, Silicon Motion Technology Corp. (NASDAQ:SIMO) also found itself in the middle of takeover speculation. Shares rose amid reports that the company is considering a potential sale. SIMO-$83.50 SIMO Silicon Motion Technology Corporation $83.586.49(+8.42%)<------------
Hi everyone. I ma back in NYC and under heavy NFL draft duties... sorry for the abbreviated take... XAIR SBEV SIMO